| Item Type | Name |
|
Concept
|
Acute Disease
|
|
Concept
|
Adenine
|
|
Concept
|
Psychology, Adolescent
|
|
Concept
|
Alopecia Areata
|
|
Concept
|
Aminopterin
|
|
Concept
|
Activities of Daily Living
|
|
Concept
|
Adenosine
|
|
Concept
|
Anti-Infective Agents
|
|
Concept
|
Antigen-Antibody Complex
|
|
Concept
|
Antibodies, Neoplasm
|
|
Concept
|
Aged, 80 and over
|
|
Concept
|
Aldehyde Reductase
|
|
Concept
|
Australia
|
|
Concept
|
Asparagine
|
|
Concept
|
Anemia, Refractory, with Excess of Blasts
|
|
Concept
|
beta 2-Microglobulin
|
|
Concept
|
Adolescent
|
|
Concept
|
Adenine Nucleotides
|
|
Concept
|
Aged
|
|
Concept
|
Allopurinol
|
|
Concept
|
Blood Component Removal
|
|
Concept
|
Alkylating Agents
|
|
Concept
|
Amino Acid Sequence
|
|
Concept
|
Acyclovir
|
|
Concept
|
Adult
|
|
Concept
|
Busulfan
|
|
Concept
|
Psychology, Child
|
|
Concept
|
Amsacrine
|
|
Concept
|
Antifungal Agents
|
|
Concept
|
Anemia, Sideroblastic
|
|
Concept
|
Antiviral Agents
|
|
Concept
|
Anemia, Refractory
|
|
Concept
|
Chromosome Banding
|
|
Concept
|
Chromosomes, Human, Pair 11
|
|
Concept
|
Chromosomes, Human, Pair 2
|
|
Concept
|
Chromosomes, Human, Pair 6
|
|
Concept
|
Arabinofuranosylcytosine Triphosphate
|
|
Concept
|
Analysis of Variance
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Chromosomes, Human, Pair 8
|
|
Concept
|
Arsenicals
|
|
Concept
|
Cyclosporins
|
|
Concept
|
B-Lymphocytes
|
|
Concept
|
Base Sequence
|
|
Concept
|
Benzamides
|
|
Concept
|
Benzimidazoles
|
|
Concept
|
Biological Availability
|
|
Concept
|
Aspartate Carbamoyltransferase
|
|
Concept
|
Aspartic Acid
|
|
Concept
|
Atrial Fibrillation
|
|
Concept
|
Azacitidine
|
|
Concept
|
Binding Sites
|
|
Concept
|
Drug Tolerance
|
|
Concept
|
Blast Crisis
|
|
Concept
|
Biopsy, Needle
|
|
Concept
|
Bleomycin
|
|
Concept
|
Body Weight
|
|
Concept
|
Butadienes
|
|
Concept
|
Cannabis
|
|
Concept
|
Bone Marrow Examination
|
|
Concept
|
Cattle
|
|
Concept
|
Cetrimonium Compounds
|
|
Concept
|
Child
|
|
Concept
|
Breast Feeding
|
|
Concept
|
Bromodeoxyuridine
|
|
Concept
|
Chromosomes, Human, Pair 1
|
|
Concept
|
Chromosomes, Human, Pair 15
|
|
Concept
|
Chromosomes, Human, Pair 21
|
|
Concept
|
Chromosomes, Human, Pair 3
|
|
Concept
|
Chromosomes, Human, 4-5
|
|
Concept
|
Cell Transformation, Viral
|
|
Concept
|
Catalase
|
|
Concept
|
Flavonoids
|
|
Concept
|
Chromosomes, Human, Pair 12
|
|
Concept
|
Chromosomes, Human, Pair 14
|
|
Concept
|
Chromosomes, Human, 6-12 and X
|
|
Concept
|
Coma
|
|
Concept
|
Cell Transformation, Neoplastic
|
|
Concept
|
Chromosomes, Human, Pair 13
|
|
Concept
|
Chromosomes, Human, Pair 22
|
|
Concept
|
Chromosomes, Human, Pair 4
|
|
Concept
|
Burkitt Lymphoma
|
|
Concept
|
Chromosomes, Human, Pair 5
|
|
Concept
|
Chromosomes, Human, Pair 7
|
|
Concept
|
Chromosomes, Human, 13-15
|
|
Concept
|
Cisplatin
|
|
Concept
|
Leucovorin
|
|
Concept
|
Clinical Competence
|
|
Concept
|
C-Reactive Protein
|
|
Concept
|
Glucosephosphate Dehydrogenase
|
|
Concept
|
Creatinine
|
|
Concept
|
Chromosomes, Human, Pair 20
|
|
Concept
|
Chromosomes, Human, 16-18
|
|
Concept
|
Chromosomes, Human, 21-22 and Y
|
|
Concept
|
Hematocrit
|
|
Concept
|
Colony-Stimulating Factors
|
|
Concept
|
Cytochalasin B
|
|
Concept
|
Dacarbazine
|
|
Concept
|
Imidazoles
|
|
Concept
|
Dimethyl Sulfoxide
|
|
Concept
|
Dinitrobenzenes
|
|
Concept
|
Cytochalasins
|
|
Concept
|
Drug Synergism
|
|
Concept
|
Immunosuppressive Agents
|
|
Concept
|
Interleukin-2
|
|
Concept
|
Interleukins
|
|
Concept
|
Leukemia, Erythroblastic, Acute
|
|
Concept
|
Cause of Death
|
|
Concept
|
Child, Preschool
|
|
Concept
|
Dogs
|
|
Concept
|
Cyclophosphamide
|
|
Concept
|
Daunorubicin
|
|
Concept
|
Glucocorticoids
|
|
Concept
|
Hemangioma
|
|
Concept
|
Histamine H2 Antagonists
|
|
Concept
|
Leukemia, Lymphoid
|
|
Concept
|
Immunologic Factors
|
|
Concept
|
Chromosomes, Human, Pair 17
|
|
Concept
|
Chromosomes, Human, Pair 9
|
|
Concept
|
Chromosomes, Human, 19-20
|
|
Concept
|
Amifostine
|
|
Concept
|
Etoposide
|
|
Concept
|
Expert Testimony
|
|
Concept
|
Cost-Benefit Analysis
|
|
Concept
|
Depression
|
|
Concept
|
Cytarabine
|
|
Concept
|
Drug Interactions
|
|
Concept
|
Diphtheria Toxin
|
|
Concept
|
Drug Resistance
|
|
Concept
|
Infant, Newborn
|
|
Concept
|
Interferons
|
|
Concept
|
Emergency Medical Technicians
|
|
Concept
|
Microtubule-Associated Proteins
|
|
Concept
|
Fingers
|
|
Concept
|
Neoplasms, Multiple Primary
|
|
Concept
|
Neoplasms, Radiation-Induced
|
|
Concept
|
Killer Cells, Natural
|
|
Concept
|
Harringtonines
|
|
Concept
|
Obesity
|
|
Concept
|
T-Lymphocytes, Helper-Inducer
|
|
Concept
|
Histocytochemistry
|
|
Concept
|
Dose-Response Relationship, Drug
|
|
Concept
|
Laryngeal Neoplasms
|
|
Concept
|
Liposomes
|
|
Concept
|
Immunoblastic Lymphadenopathy
|
|
Concept
|
Immunoglobulin Heavy Chains
|
|
Concept
|
Eosinophils
|
|
Concept
|
Herpesvirus 4, Human
|
|
Concept
|
Escherichia coli
|
|
Concept
|
Hyperphagia
|
|
Concept
|
Flow Cytometry
|
|
Concept
|
Infant
|
|
Concept
|
Interleukin-1
|
|
Concept
|
International Cooperation
|
|
Concept
|
Multigene Family
|
|
Concept
|
Glutathione
|
|
Concept
|
Granulocytes
|
|
Concept
|
Lepidoptera
|
|
Concept
|
Leukocytes, Mononuclear
|
|
Concept
|
Lymphocyte Depletion
|
|
Concept
|
Lymphoproliferative Disorders
|
|
Concept
|
Mechlorethamine
|
|
Concept
|
Lactation
|
|
Concept
|
Leukocytes
|
|
Concept
|
Muscle Cramp
|
|
Concept
|
Pilot Projects
|
|
Concept
|
Avian Myeloblastosis Virus
|
|
Concept
|
Myeloproliferative Disorders
|
|
Concept
|
Methylnitronitrosoguanidine
|
|
Concept
|
Markov Chains
|
|
Concept
|
European Union
|
|
Concept
|
Pregnancy
|
|
Concept
|
Immunoglobulin Isotypes
|
|
Concept
|
Immunoglobulin Variable Region
|
|
Concept
|
Opportunistic Infections
|
|
Concept
|
Molecular Sequence Data
|
|
Concept
|
Palliative Care
|
|
Concept
|
Methotrexate
|
|
Concept
|
Mice, Inbred C57BL
|
|
Concept
|
Middle Aged
|
|
Concept
|
Mitogens
|
|
Concept
|
Mitoxantrone
|
|
Concept
|
Myelodysplastic Syndromes
|
|
Concept
|
Patents as Topic
|
|
Concept
|
Interleukin-3
|
|
Concept
|
Isocitrate Dehydrogenase
|
|
Concept
|
Isoleucine
|
|
Concept
|
Neutrophils
|
|
Concept
|
Nitriles
|
|
Concept
|
Nitrosourea Compounds
|
|
Concept
|
Naphthalenes
|
|
Concept
|
Philadelphia Chromosome
|
|
Concept
|
Ovarian Neoplasms
|
|
Concept
|
Liver
|
|
Concept
|
Safety
|
|
Concept
|
Semantic Differential
|
|
Concept
|
Patient Advocacy
|
|
Concept
|
Peripheral Nervous System Diseases
|
|
Concept
|
Melphalan
|
|
Concept
|
Patients
|
|
Concept
|
Sex Characteristics
|
|
Concept
|
Metaphase
|
|
Concept
|
Stimulation, Chemical
|
|
Concept
|
Phosphorylation
|
|
Concept
|
Mouth Mucosa
|
|
Concept
|
Feeding Behavior
|
|
Concept
|
Probability
|
|
Concept
|
Preoperative Care
|
|
Concept
|
Prescription Fees
|
|
Concept
|
Protein-Tyrosine Kinases
|
|
Concept
|
Proto-Oncogene Proteins
|
|
Concept
|
Purine Nucleosides
|
|
Concept
|
Genetic Markers
|
|
Concept
|
Hodgkin Disease
|
|
Concept
|
Regression Analysis
|
|
Concept
|
Radiation-Sensitizing Agents
|
|
Concept
|
Risk Factors
|
|
Concept
|
RNA, Neoplasm
|
|
Concept
|
Rubber
|
|
Concept
|
Prothrombin Time
|
|
Concept
|
Quinolines
|
|
Concept
|
Quinoxalines
|
|
Concept
|
Interferon-gamma
|
|
Concept
|
Intestinal Absorption
|
|
Concept
|
Social Support
|
|
Concept
|
RNA Probes
|
|
Concept
|
Regulatory Sequences, Nucleic Acid
|
|
Concept
|
Ribonucleoproteins
|
|
Concept
|
Leukemia, B-Cell
|
|
Concept
|
Interleukin-6
|
|
Concept
|
Respiratory Insufficiency
|
|
Concept
|
Risk
|
|
Concept
|
Stress, Psychological
|
|
Concept
|
Hematologic Tests
|
|
Concept
|
Sulfonic Acids
|
|
Concept
|
Humans
|
|
Concept
|
Leukemia, Radiation-Induced
|
|
Concept
|
Leukocyte Count
|
|
Concept
|
Complement C1q
|
|
Concept
|
Body Mass Index
|
|
Concept
|
Ticlopidine
|
|
Concept
|
Tomography, X-Ray Computed
|
|
Concept
|
Tooth Extraction
|
|
Concept
|
Tretinoin
|
|
Concept
|
Thalidomide
|
|
Concept
|
Interferon Type I
|
|
Concept
|
Thionucleotides
|
|
Concept
|
United States Food and Drug Administration
|
|
Concept
|
Sulfuric Acids
|
|
Concept
|
Superoxide Dismutase
|
|
Concept
|
Interleukin-9
|
|
Concept
|
Practice Guidelines as Topic
|
|
Concept
|
Voluntary Health Agencies
|
|
Concept
|
Warfarin
|
|
Concept
|
Thioguanine
|
|
Concept
|
Ultraviolet Rays
|
|
Concept
|
Multicenter Studies as Topic
|
|
Concept
|
Leukemia, Lymphocytic, Chronic, B-Cell
|
|
Concept
|
Leukemia, Myeloid, Accelerated Phase
|
|
Concept
|
Mercaptopurine
|
|
Concept
|
Lovastatin
|
|
Concept
|
Lymphocytosis
|
|
Concept
|
Lymphoma, Follicular
|
|
Concept
|
Hematopoietic Stem Cell Transplantation
|
|
Concept
|
Oncogene Proteins
|
|
Concept
|
Oncogene Proteins, Fusion
|
|
Concept
|
Proportional Hazards Models
|
|
Concept
|
Risk Assessment
|
|
Concept
|
Drug Resistance, Neoplasm
|
|
Concept
|
Myeloablative Agonists
|
|
Concept
|
Reverse Transcriptase Polymerase Chain Reaction
|
|
Concept
|
Vidarabine
|
|
Concept
|
Valine
|
|
Concept
|
Treatment Refusal
|
|
Concept
|
Central Nervous System Neoplasms
|
|
Concept
|
Up-Regulation
|
|
Concept
|
Cryopreservation
|
|
Concept
|
Quinolones
|
|
Concept
|
Metabolic Clearance Rate
|
|
Concept
|
Neoplasms, Second Primary
|
|
Concept
|
Leukemia, Prolymphocytic
|
|
Concept
|
Ganciclovir
|
|
Concept
|
NAD(P)H Dehydrogenase (Quinone)
|
|
Concept
|
Lymph Nodes
|
|
Concept
|
Lymphoma
|
|
Concept
|
Mortality
|
|
Concept
|
Multiple Myeloma
|
|
Concept
|
DNA Probes
|
|
Concept
|
Interleukin-4
|
|
Concept
|
Comorbidity
|
|
Concept
|
Stem Cell Transplantation
|
|
Concept
|
Foscarnet
|
|
Concept
|
Drug Approval
|
|
Concept
|
Proto-Oncogene Proteins c-myc
|
|
Concept
|
Occupational Exposure
|
|
Concept
|
Hematopoietic Cell Growth Factors
|
|
Concept
|
Proto-Oncogene Proteins c-abl
|
|
Concept
|
Hypopigmentation
|
|
Concept
|
Methylation
|
|
Concept
|
Paraffin Embedding
|
|
Concept
|
Neoplasm Metastasis
|
|
Concept
|
Neoplasm Recurrence, Local
|
|
Concept
|
Ubiquitin Thiolesterase
|
|
Concept
|
RNA-Binding Proteins
|
|
Concept
|
Tissue Fixation
|
|
Concept
|
Point Mutation
|
|
Concept
|
Interferon-alpha
|
|
Concept
|
Antibodies, Bispecific
|
|
Concept
|
Mice, Knockout
|
|
Concept
|
DNA, Complementary
|
|
Concept
|
Disease Progression
|
|
Concept
|
Telomerase
|
|
Concept
|
Transplantation Conditioning
|
|
Concept
|
Inhibitor of Apoptosis Proteins
|
|
Concept
|
Simvastatin
|
|
Concept
|
Antineoplastic Agents, Alkylating
|
|
Concept
|
Antigens, CD19
|
|
Concept
|
src-Family Kinases
|
|
Concept
|
Angiogenesis Inhibitors
|
|
Concept
|
Staurosporine
|
|
Concept
|
Fanconi Anemia Complementation Group D2 Protein
|
|
Concept
|
Receptor Protein-Tyrosine Kinases
|
|
Concept
|
Mutation, Missense
|
|
Concept
|
Lymphocyte Count
|
|
Concept
|
Immunoconjugates
|
|
Concept
|
Case Management
|
|
Concept
|
Models, Econometric
|
|
Concept
|
Cladribine
|
|
Concept
|
Reactive Oxygen Species
|
|
Concept
|
In Situ Hybridization, Fluorescence
|
|
Concept
|
Fatal Outcome
|
|
Concept
|
Ontario
|
|
Concept
|
Peripheral Blood Stem Cell Transplantation
|
|
Concept
|
Consensus
|
|
Concept
|
PubMed
|
|
Concept
|
Granulocyte Precursor Cells
|
|
Concept
|
Proto-Oncogene Proteins c-mdm2
|
|
Concept
|
Fanconi Anemia Complementation Group A Protein
|
|
Concept
|
Proto-Oncogene Proteins c-bcl-2
|
|
Concept
|
Area Under Curve
|
|
Concept
|
Anthracyclines
|
|
Concept
|
Proto-Oncogene Proteins c-kit
|
|
Concept
|
Patient Participation
|
|
Concept
|
Oligonucleotide Array Sequence Analysis
|
|
Concept
|
Receptors, Thrombopoietin
|
|
Concept
|
Mitogen-Activated Protein Kinase Kinases
|
|
Concept
|
Catalytic Domain
|
|
Concept
|
Proto-Oncogene Proteins c-myb
|
|
Concept
|
CCAAT-Enhancer-Binding Proteins
|
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p21
|
|
Concept
|
Peritoneal Dialysis, Continuous Ambulatory
|
|
Concept
|
Peritonitis
|
|
Concept
|
Phthalazines
|
|
Concept
|
Platelet Count
|
|
Concept
|
Polyethylene Glycols
|
|
Concept
|
WT1 Proteins
|
|
Concept
|
Placebos
|
|
Concept
|
Prodrugs
|
|
Concept
|
Mice
|
|
Concept
|
Pyrazoles
|
|
Concept
|
Pyrimidinones
|
|
Concept
|
Radiation-Protective Agents
|
|
Concept
|
Saccharomyces cerevisiae
|
|
Concept
|
Scrotum
|
|
Concept
|
Research Design
|
|
Concept
|
Sulfonamides
|
|
Concept
|
Biomedical Research
|
|
Concept
|
Thrombopoietin
|
|
Concept
|
Receptors, Vascular Endothelial Growth Factor
|
|
Concept
|
Chimerism
|
|
Concept
|
Dioxygenases
|
|
Concept
|
Preoperative Period
|
|
Concept
|
Proto-Oncogene Proteins c-cbl
|
|
Concept
|
Triazoles
|
|
Concept
|
ADP-ribosyl Cyclase 1
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Concept
|
Urate Oxidase
|
|
Concept
|
Sex Factors
|
|
Concept
|
Sister Chromatid Exchange
|
|
Concept
|
Spleen
|
|
Concept
|
Stereoisomerism
|
|
Concept
|
Vincristine
|
|
Concept
|
Adaptor Proteins, Signal Transducing
|
|
Concept
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
|
Concept
|
Temperature
|
|
Concept
|
Blotting, Western
|
|
Concept
|
Tumor Lysis Syndrome
|
|
Concept
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
|
|
Concept
|
Down-Regulation
|
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p15
|
|
Concept
|
Multivariate Analysis
|
|
Concept
|
Logistic Models
|
|
Concept
|
Thiazoles
|
|
Concept
|
CD4-CD8 Ratio
|
|
Concept
|
Vinblastine
|
|
Concept
|
Xylose
|
|
Concept
|
Blotting, Southern
|
|
Concept
|
Blotting, Northern
|
|
Concept
|
Reproducibility of Results
|
|
Concept
|
Leukemia-Lymphoma, Adult T-Cell
|
|
Concept
|
Leukemia, Myeloid, Chronic-Phase
|
|
Concept
|
Abnormal Karyotype
|
|
Concept
|
Survival Rate
|
|
Concept
|
Fusion Proteins, bcr-abl
|
|
Concept
|
Lymphocyte Subsets
|
|
Concept
|
Polymerase Chain Reaction
|
|
Concept
|
Granulocyte Colony-Stimulating Factor
|
|
Concept
|
Proto-Oncogene Proteins p21(ras)
|
|
Concept
|
Patient Selection
|
|
Concept
|
Lymphoma, T-Cell
|
|
Concept
|
CD13 Antigens
|
|
Concept
|
Leukemic Infiltration
|
|
Concept
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
|
Concept
|
Myeloid Progenitor Cells
|
|
Concept
|
Drug Resistance, Multiple
|
|
Concept
|
Models, Economic
|
|
Concept
|
Cell Lineage
|
|
Concept
|
Ideal Body Weight
|
|
Concept
|
O(6)-Methylguanine-DNA Methyltransferase
|
|
Concept
|
Mood Disorders
|
|
Concept
|
Heterogeneous-Nuclear Ribonucleoprotein K
|
|
Concept
|
Pneumococcal Vaccines
|
|
Concept
|
Drug Resistance, Viral
|
|
Concept
|
Tumor Suppressor Proteins
|
|
Concept
|
STAT5 Transcription Factor
|
|
Concept
|
Karyotype
|
|
Concept
|
Janus Kinase 2
|
|
Concept
|
Nanoparticles
|
|
Concept
|
Genome-Wide Association Study
|
|
Concept
|
Multiplex Polymerase Chain Reaction
|
|
Concept
|
Heterogeneous-Nuclear Ribonucleoproteins
|
|
Concept
|
RNA-Binding Protein FUS
|
|
Concept
|
RNA, Small Interfering
|
|
Concept
|
Cord Blood Stem Cell Transplantation
|
|
Concept
|
Antibodies, Monoclonal, Murine-Derived
|
|
Concept
|
Telomere Homeostasis
|
|
Concept
|
Depsipeptides
|
|
Concept
|
Suppressor of Cytokine Signaling Proteins
|
|
Concept
|
ZAP-70 Protein-Tyrosine Kinase
|
|
Concept
|
Myeloid-Lymphoid Leukemia Protein
|
|
Concept
|
fms-Like Tyrosine Kinase 3
|
|
Concept
|
Kaplan-Meier Estimate
|
|
Concept
|
Drug Discovery
|
|
Concept
|
Diet, High-Fat
|
|
Concept
|
Aluminum Silicates
|
|
Concept
|
Anti-Bacterial Agents
|
|
Concept
|
Immunotoxins
|
|
Concept
|
Avian Leukosis Virus
|
|
Concept
|
Blood Cell Count
|
|
Concept
|
Body Surface Area
|
|
Concept
|
Brain Neoplasms
|
|
Concept
|
Carbolines
|
|
Concept
|
Chlorambucil
|
|
Concept
|
Chromatin
|
|
Concept
|
Chromosomes, Human
|
|
Concept
|
Chromosomes, Human, Pair 16
|
|
Concept
|
Consensus Development Conferences as Topic
|
|
Concept
|
Cytosine
|
|
Concept
|
Deoxycytidine
|
|
Concept
|
Drug Eruptions
|
|
Concept
|
Doxorubicin
|
|
Concept
|
Haemophilus influenzae
|
|
Concept
|
Histiocytes
|
|
Concept
|
Injections, Subcutaneous
|
|
Concept
|
Leukemia, Hairy Cell
|
|
Concept
|
Lymphocytes
|
|
Concept
|
Lymphoma, Non-Hodgkin
|
|
Concept
|
Mitomycins
|
|
Concept
|
Monocytes
|
|
Concept
|
Oxides
|
|
Concept
|
Paramyxoviridae
|
|
Concept
|
Patient Compliance
|
|
Concept
|
Phenotype
|
|
Concept
|
Predictive Value of Tests
|
|
Concept
|
Procarbazine
|
|
Concept
|
Prospective Studies
|
|
Concept
|
Ricin
|
|
Concept
|
Staining and Labeling
|
|
Concept
|
T-Lymphocytes
|
|
Concept
|
Restriction Mapping
|
|
Concept
|
Idarubicin
|
|
Concept
|
Leukemia, T-Cell
|
|
Concept
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
|
|
Concept
|
Interleukin-5
|
|
Concept
|
Tumor Suppressor Protein p53
|
|
Concept
|
Granulocyte-Macrophage Colony-Stimulating Factor
|
|
Concept
|
Cytokines
|
|
Concept
|
Mutagenesis, Insertional
|
|
Concept
|
Oligonucleotides, Antisense
|
|
Concept
|
Mitomycin
|
|
Concept
|
DNA Primers
|
|
Concept
|
Neoplasm, Residual
|
|
Concept
|
Polymorphism, Single-Stranded Conformational
|
|
Concept
|
Bridged Bicyclo Compounds, Heterocyclic
|
|
Concept
|
Genetic Predisposition to Disease
|
|
Concept
|
Physical Chromosome Mapping
|
|
Concept
|
Maximum Tolerated Dose
|
|
Concept
|
Myeloid Cells
|
|
Concept
|
MicroRNAs
|
|
Concept
|
Cyclin-Dependent Kinase 9
|
|
Concept
|
Proto-Oncogene Proteins c-akt
|
|
Concept
|
Transcription Factor CHOP
|
|
Concept
|
Medication Adherence
|
|
Concept
|
Young Adult
|
|
Concept
|
Drug Substitution
|
|
Concept
|
Musculoskeletal Pain
|
|
Academic Article
|
Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases.
|
|
Academic Article
|
Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays.
|
|
Academic Article
|
Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia.
|
|
Academic Article
|
Clinical, morphologic, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia.
|
|
Academic Article
|
Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.
|
|
Academic Article
|
Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases.
|
|
Academic Article
|
Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).
|
|
Academic Article
|
Familial myeloid leukemia associated with loss of the long arm of chromosome 5.
|
|
Academic Article
|
Myeloid leukemia after hematotoxins.
|
|
Academic Article
|
Establishment and characterization of a megakaryoblast cell line with amplification of MLL.
|
|
Academic Article
|
Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia.
|
|
Academic Article
|
Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map.
|
|
Academic Article
|
Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map.
|
|
Academic Article
|
Myeloid leukemia after cytotoxic therapy and other hematotoxins.
|
|
Academic Article
|
Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
|
|
Academic Article
|
Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia.
|
|
Academic Article
|
Metastatic adenocarcinoma arising in a congenital foregut cyst of the esophagus: a case report with review of the literature.
|
|
Academic Article
|
Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine).
|
|
Academic Article
|
dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53.
|
|
Academic Article
|
CBFA2(AML1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy.
|
|
Academic Article
|
Pseudo-Gaucher histiocytes identified up to 1 year after transplantation for CML are BCR/ABL-positive.
|
|
Academic Article
|
Detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization to interphase cells: a simple and sensitive method.
|
|
Academic Article
|
Dose-intensive therapy for adult acute lymphoblastic leukemia.
|
|
Academic Article
|
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia.
|
|
Academic Article
|
Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q).
|
|
Academic Article
|
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
|
|
Academic Article
|
New agents for induction and postremission therapy of acute myeloid leukemia.
|
|
Academic Article
|
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
|
|
Academic Article
|
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
|
|
Academic Article
|
Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia?
|
|
Academic Article
|
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
|
|
Academic Article
|
t(1;3)(p36;p21) is a recurring therapy-related translocation.
|
|
Academic Article
|
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
|
|
Academic Article
|
Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.
|
|
Academic Article
|
Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).
|
|
Academic Article
|
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).
|
|
Academic Article
|
Acute lymphoblastic leukaemia: diagnosis and classification.
|
|
Academic Article
|
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.
|
|
Academic Article
|
Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia.
|
|
Academic Article
|
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
|
|
Academic Article
|
Progress and challenges in the therapy of adult acute lymphoblastic leukemia.
|
|
Academic Article
|
Polymorphisms in the MLL breakpoint cluster region (BCR).
|
|
Academic Article
|
Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B.
|
|
Academic Article
|
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
|
|
Academic Article
|
Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.
|
|
Academic Article
|
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.
|
|
Academic Article
|
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
|
|
Academic Article
|
Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature.
|
|
Academic Article
|
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
|
|
Academic Article
|
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
|
|
Academic Article
|
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.
|
|
Academic Article
|
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.
|
|
Academic Article
|
Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.
|
|
Academic Article
|
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
|
|
Academic Article
|
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.
|
|
Academic Article
|
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
|
|
Academic Article
|
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.
|
|
Academic Article
|
Management of acute lymphoblastic leukemia in older patients.
|
|
Academic Article
|
A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies.
|
|
Academic Article
|
Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B.
|
|
Academic Article
|
Trisomy 6: a recurring cytogenetic abnormality associated with marrow hypoplasia.
|
|
Academic Article
|
Therapy-related myeloid leukaemia: a model for leukemogenesis in humans.
|
|
Academic Article
|
Myelodysplasia: when to treat and how.
|
|
Academic Article
|
Daily companionship in late childhood and early adolescence: changing developmental contexts.
|
|
Academic Article
|
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review.
|
|
Academic Article
|
Gene expression profiles in acute myeloid leukemia with common translocations using SAGE.
|
|
Academic Article
|
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant.
|
|
Academic Article
|
Deletions of interferon genes in acute lymphoblastic leukemia.
|
|
Academic Article
|
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
|
|
Academic Article
|
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
|
|
Academic Article
|
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
|
|
Academic Article
|
Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia.
|
|
Academic Article
|
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.
|
|
Academic Article
|
Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11).
|
|
Academic Article
|
Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628.
|
|
Academic Article
|
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
|
|
Academic Article
|
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
|
|
Academic Article
|
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
|
|
Academic Article
|
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma.
|
|
Academic Article
|
Acute lymphoblastic leukemia: older patients and newer drugs.
|
|
Academic Article
|
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review.
|
|
Academic Article
|
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
|
|
Academic Article
|
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
|
|
Academic Article
|
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
|
|
Academic Article
|
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).
|
|
Academic Article
|
Clinicopathologic manifestations and breakpoints of the t(3;5) in patients with acute nonlymphocytic leukemia.
|
|
Academic Article
|
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.
|
|
Academic Article
|
High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.
|
|
Academic Article
|
Role of allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia.
|
|
Academic Article
|
The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia.
|
|
Academic Article
|
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
|
|
Academic Article
|
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
|
|
Academic Article
|
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.
|
|
Academic Article
|
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
|
|
Academic Article
|
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.
|
|
Academic Article
|
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.
|
|
Academic Article
|
Acute leukemia occurring after radiotherapy and chemotherapy with a nitrosourea, PCNU.
|
|
Academic Article
|
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.
|
|
Academic Article
|
Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes.
|
|
Academic Article
|
Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis.
|
|
Academic Article
|
Acral lividosis--a sign of myeloproliferative diseases. Hyperleukocytosis syndrome in chronic myelogenous leukemia.
|
|
Academic Article
|
Alcohol and marijuana use in adolescents' daily lives: a random sample of experiences.
|
|
Academic Article
|
Neutrophils are required for the DNA synthetic response of human lymphocytes to mevalonic acid: evidence suggesting that a nonsterol product of mevalonate is involved.
|
|
Academic Article
|
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
|
|
Academic Article
|
Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II.
|
|
Academic Article
|
High-dose Ara-C plus VM-26 in adult acute lymphoblastic leukemia.
|
|
Academic Article
|
A morphologic and cytochemical study of acute myelomonocytic leukemia with abnormal marrow eosinophils associated with inv(16)(p13q22).
|
|
Academic Article
|
Association of a chromosomal 3;21 translocation with the blast phase of chronic myelogenous leukemia.
|
|
Academic Article
|
Assignment of the GM-CSF, CSF-1, and FMS genes to human chromosome 5 provides evidence for linkage of a family of genes regulating hematopoiesis and for their involvement in the deletion (5q) in myeloid disorders.
|
|
Academic Article
|
Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia.
|
|
Academic Article
|
Cytochalasin B is a potent mitogen for chronic lymphocytic leukemia cells in vitro.
|
|
Academic Article
|
Neutrophil-assisted DNA synthesis by human lymphocytes in response to mevalonic acid; enhancement by cytochalasin B.
|
|
Academic Article
|
Cholesterol and mevalonic acid are independent requirements for the in vitro proliferation of human bone marrow granulocyte progenitor cells: studies using ML-236B.
|
|
Academic Article
|
Processing of bone marrow for transplantation: development of a mononuclear cell enrichment protocol.
|
|
Academic Article
|
The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia.
|
|
Academic Article
|
Der(5)t(5;7)(q11.2;p11.2): a new recurring abnormality in malignant myeloid disorders.
|
|
Academic Article
|
Acute myelomonocytic leukemia with abnormal eosinophils presenting as an ovarian mass: a report of two cases and a review of the literature.
|
|
Academic Article
|
Assignment of CSF-1 to 5q33.1: evidence for clustering of genes regulating hematopoiesis and for their involvement in the deletion of the long arm of chromosome 5 in myeloid disorders.
|
|
Academic Article
|
Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemia.
|
|
Academic Article
|
Chromosomal loss and deletion are the most common mechanisms for loss of heterozygosity from chromosomes 5 and 7 in malignant myeloid disorders.
|
|
Academic Article
|
Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission.
|
|
Academic Article
|
Interleukin-4 and interleukin-5 map to human chromosome 5 in a region encoding growth factors and receptors and are deleted in myeloid leukemias with a del(5q).
|
|
Academic Article
|
Rates of cholesterol biosynthesis are related to early differentiation in acute non-lymphocytic leukaemia cells.
|
|
Academic Article
|
The predictive value of initial cytogenetic studies in 148 adults with acute nonlymphocytic leukemia: a 12-year study (1970-1982).
|
|
Academic Article
|
The DNA synthetic response of normal and abnormal human lymphocytes to mevalonic acid: the role of granulocytes as a helper population.
|
|
Academic Article
|
Complex rearrangement of the T cell receptor in large granular lymphocytosis associated with myeloid suppression.
|
|
Academic Article
|
Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association.
|
|
Academic Article
|
Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: A Leukemia Intergroup pilot study.
|
|
Academic Article
|
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
|
|
Academic Article
|
Psychosocial symptomatology, personal growth, and development among young adult patients following the diagnosis of leukemia or lymphoma.
|
|
Academic Article
|
Detection of MLL gene rearrangements in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study.
|
|
Academic Article
|
Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid disorders.
|
|
Academic Article
|
Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7.
|
|
Academic Article
|
Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.
|
|
Academic Article
|
Response to 5-azacytidine in patients with refractory acute nonlymphocytic leukemia and association with chromosome findings.
|
|
Academic Article
|
Use of decline in D-xylose absorption to predict infection following intensive chemotherapy.
|
|
Academic Article
|
Mevalonic acid induces DNA synthesis in chronic lymphocytic leukemia cells.
|
|
Academic Article
|
The strategic role of laparotomy in staging Hodgkin's disease.
|
|
Academic Article
|
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.
|
|
Academic Article
|
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
|
|
Academic Article
|
Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.
|
|
Academic Article
|
Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion.
|
|
Academic Article
|
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
A recurring chromosome rearrangement, dic(16;22), in acute nonlymphocytic leukemia.
|
|
Academic Article
|
Chromosome changes in hematologic malignancies.
|
|
Academic Article
|
Establishment of a leukemia cell line with i(12p) from a patient with a mediastinal germ cell tumor and acute lymphoblastic leukemia.
|
|
Academic Article
|
A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.
|
|
Academic Article
|
Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.
|
|
Academic Article
|
Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP.
|
|
Academic Article
|
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.
|
|
Academic Article
|
Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia.
|
|
Academic Article
|
Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop.
|
|
Academic Article
|
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
|
|
Academic Article
|
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
|
|
Academic Article
|
RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
|
|
Academic Article
|
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461.
|
|
Academic Article
|
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
|
|
Academic Article
|
t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia.
|
|
Academic Article
|
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
|
|
Academic Article
|
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.
|
|
Academic Article
|
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase.
|
|
Academic Article
|
FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.
|
|
Academic Article
|
Treatment-influenced associations of PML-RARa mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.
|
|
Academic Article
|
'Golden tongue' syndrome caused by Ramichloridium schulzeri.
|
|
Academic Article
|
Nonrandom chromosome abnormalities in angioimmunoblastic lymphadenopathy.
|
|
Academic Article
|
Hypercalcemia and lytic bone lesions in a patient with B-cell non-Hodgkin's lymphoma.
|
|
Academic Article
|
Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma.
|
|
Academic Article
|
Children and adolescents in a changing media world.
|
|
Academic Article
|
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
|
|
Academic Article
|
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.
|
|
Academic Article
|
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
|
|
Academic Article
|
Immune reconstitution after combined haploidentical and umbilical cord blood transplant.
|
|
Academic Article
|
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
|
|
Academic Article
|
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.
|
|
Academic Article
|
The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q).
|
|
Academic Article
|
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.
|
|
Academic Article
|
A comparison study of chest tube thoracostomy: air medical crew and in-hospital trauma service.
|
|
Academic Article
|
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.
|
|
Academic Article
|
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
|
|
Academic Article
|
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
|
|
Academic Article
|
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
|
|
Academic Article
|
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
|
|
Academic Article
|
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
|
|
Academic Article
|
Insect defenses against phototoxic plant chemicals.
|
|
Academic Article
|
Daily emotional states as reported by children and adolescents.
|
|
Academic Article
|
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily.
|
|
Academic Article
|
Overexpression and knockout of miR-126 both promote leukemogenesis.
|
|
Academic Article
|
Is there a best TKI for chronic phase CML?
|
|
Academic Article
|
Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.
|
|
Academic Article
|
Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children's Oncology Group incorporating nelarabine into front-line therapy.
|
|
Academic Article
|
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
|
|
Academic Article
|
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.
|
|
Academic Article
|
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.
|
|
Academic Article
|
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
|
|
Academic Article
|
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
|
|
Academic Article
|
FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase.
|
|
Academic Article
|
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.
|
|
Academic Article
|
ATP-binding cassette (ABC) proteins in untreated acute myeloid leukemia (AML) in patients 60 years and older (CALGB 9760).
|
|
Academic Article
|
Patients (pts) with acute myeloid leukemia (AML) and mutant RAS benefit from high-dose cytarabine (HDAC) intensification: A Cancer and Leukemia Group B (CALGB) study.
|
|
Academic Article
|
Comparison of de novo vs. therapy-related acute leukemia (AL) and myelodysplastic syndromes (MDS) in adults with balanced chromosome aberrations of 11q23.
|
|
Academic Article
|
Beta-carboline alkaloids: mechanisms of phototoxicity to bacteria and insects.
|
|
Academic Article
|
Treatment of Acute Promyelocytic Leukemia in Adults.
|
|
Academic Article
|
Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).
|
|
Academic Article
|
Surfactant-assisted UV-photolysis of nitroarenes.
|
|
Academic Article
|
Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).
|
|
Academic Article
|
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
|
|
Academic Article
|
Imatinib is still recommended for frontline therapy for CML.
|
|
Academic Article
|
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.
|
|
Academic Article
|
Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.
|
|
Academic Article
|
Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?
|
|
Academic Article
|
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.
|
|
Academic Article
|
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.
|
|
Academic Article
|
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.
|
|
Academic Article
|
Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force.
|
|
Academic Article
|
Economics influences therapy decisions in chronic myeloid leukaemia: should it?
|
|
Academic Article
|
Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy.
|
|
Academic Article
|
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
|
|
Academic Article
|
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.
|
|
Academic Article
|
Obesity in children with acute promyelocytic leukemia: What is its prevalence and prognostic significance?
|
|
Academic Article
|
Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101.
|
|
Academic Article
|
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
|
|
Academic Article
|
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
|
|
Academic Article
|
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
|
|
Concept
|
Imatinib Mesylate
|
|
Concept
|
Rituximab
|
|
Concept
|
Dasatinib
|
|
Concept
|
Filgrastim
|
|
Concept
|
Bortezomib
|
|
Concept
|
Bendamustine Hydrochloride
|
|
Concept
|
Alpha-Ketoglutarate-Dependent Dioxygenase FTO
|
|
Concept
|
Positron Emission Tomography Computed Tomography
|
|
Concept
|
Transcriptional Regulator ERG
|
|
Concept
|
MDS1 and EVI1 Complex Locus Protein
|
|
Concept
|
RUNX1 Translocation Partner 1 Protein
|
|
Concept
|
Alemtuzumab
|
|
Concept
|
MCF-7 Cells
|
|
Concept
|
Pediatric Obesity
|
|
Concept
|
Ataxia Telangiectasia Mutated Proteins
|
|
Academic Article
|
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
|
|
Academic Article
|
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
|
|
Academic Article
|
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.
|
|
Academic Article
|
Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL.
|